Y-mAbs Therapeutics A/S: Financial statements 2023
CVR: 37053678
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Y-mAbs Therapeutics A/S (CVR 37053678) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 70,656,043 and a net result of DKK -27,748,840 compared with DKK -85,685,825 the year before. That is a decrease of 14.2% compared with the year before. Equity in the 2023 report amounted to DKK -112,689,781. The company had 59 employees in the financial year.
- Gross Profit
- DKK 70,656,043
- Profit/Loss
- DKK -27,748,840
- Equity
- DKK -112,689,781
- Total Assets
- DKK 56,658,376
- Employees
- 59
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 70.7M | -27.7M | -112.7M | 59 |
| 2022 | - | 82.3M | -85.7M | -84.9M | 101 |
| 2021 | - | 67.5M | -42.1M | -39.3M | 88 |
| 2020 | - | 82.4M | -1.2M | 2.8M | 62 |
| 2019 | - | 52M | -2.6M | 4M | 36 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of November 29, 2023, Michael Joseph Rossi has joined the board of directors of Y-mAbs Therapeutics A/S.
As of November 28, 2023, Michael Joseph Rossi is registered as adm. dir. of Y-mAbs Therapeutics A/S.
As of November 28, 2023, Thomas Gad has stepped down as adm. dir. of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2022. Gross profit came to DKK 82,332,358, and the net result was DKK -85,685,825.
About Y-mAbs Therapeutics A/S
Y-mAbs Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Vincent Sainte-Catherine. The board consists of Antoine Bernasconi (chair), Julien Forest and Vincent Sainte-Catherine. The company is owned by Y-mAbs Therapeutics, Inc.. The company has 13 employees (2026). In 2025, the company reported a gross profit of DKK 29,300,371 and a net result of DKK -38,461,598 compared with DKK -12,500,464 the year before. Equity in the 2025 report amounted to DKK -163,651,844.
